Cue Biopharma

Cue Biopharma

CUE· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -72.0% in FY2025

Usman Azam is the CEO of Cue Biopharma and was paid $1.2M in FY2025 (Dec).

Pay$100 in the stock at the end of FY24 → $28
CEO pay is from each Cue Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Daniel R. PasseriFY2025
  2. 2Matteo LevisettiFY2025
  3. 3Usman AzamFY2025
  4. 4Lucinda WarrenFY2025
  5. 5Colin SandercockFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Cue Biopharma paid its 5 named executives $5.2M in total in FY2025 (Dec). CEO Usman Azam was paid $1.2M of that.

Name
Daniel R. PasseriFormer Chief Executive Officer
Matteo LevisettiFormer Chief Medical OfficerNot disclosed
Usman AzamPresident and Chief Executive OfficerNot disclosedNot disclosed
Lucinda WarrenChief Financial and Business OfficerNot disclosedNot disclosed
Colin SandercockSVP, General Counsel and SecretaryNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Cue Biopharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Annual report10-KMar 16, 2026FY2025
Proxy statementDEF 14AMar 16, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 31, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data